non-small cell lung cancer
Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug
The companies will jointly develop and commercialize Guardant360 CDx and Guardant360 TissueNext for taletrectinib treatment in advanced and metastatic NSCLC.
Guardant Health to Integrate Lunit's AI PD-L1 Scoring Algorithm Into Tissue Test Offering
The companies have been working together since 2021 following a strategic investment by Guardant in the South Korean AI firm.
Thermo Fisher Scientific, AstraZeneca to Develop Solid Tissue and Blood-Based CDx Test
The firms will develop the NGS-based CDx for non-small cell lung cancer drug Tagrisso using the Oncomine Dx Express Test on the Genexus Dx System.
Quest Diagnostics to Offer Agilent Companion Test for Mirati Therapeutics NSCLC Treatment
Agilent's companion diagnostic for Mirati's non-small cell lung cancer treatment Krazati will be available through Quest's national healthcare network.
FDA Approves Foundation Medicine Blood Test as CDx for Rozlytrek
FoundationOne Liquid CDx, a liquid biopsy test, is the only blood-based CDx approved for the targeted cancer therapy.